MDXHEALTH, INC. is a leading molecular diagnostic company based in Irvine, CA, specializing in personalized solutions for the earlier detection of aggressive prostate cancer and urologic diseases. With a focus on delivering molecular diagnostic tests, MDXHEALTH aims to improve patient outcomes by providing accessible and affordable testing options for all patients.
Utilizing advanced technologies such as Next Generation Sequencing and qPCR, MDXHEALTH offers tailored reports that integrate clinical, pathological, and genomic insights to inform treatment decisions. Their Genomic Prostate Score (GPS) test is the only commercially available test that predicts tumor aggressiveness and provides comprehensive risk assessments for high-grade disease, metastasis, and PCa-specific death. With a commitment to precision and innovation, MDXHEALTH is dedicated to improving the detection and management of urologic diseases.
Generated from the website